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Knowledge and provision of misoprostol
in Senegal pharmacies
SUMMARY
• Pharmacies are key service delivery points for many women in Senegal.
• Currently, the majority of pharmacy workers do not have the knowledge to
safely provide misoprostol to clients or health providers.
• Pharmacy workers’ knowledge of misoprostol needs to be strengthened.
• Further, the supply chain in Senegal needs to be strengthened to ensure
access to all essential medications, including misoprostol.
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INTRODUCTION
Post-partum haemorrhage (PPH) and
complications related to unsafe abortion are
direct causes of maternal death in low- and
middle-income countries; women, their
families, and their communities all suffer as a
result.
In Senegal, actions to eradicate this problem
have made significant advances in recent
years. However, there is much left to do -Senegal has not achieved Millennium
Development Goal V, which called for the
reduction of its maternal mortality ratio from
392 to 127 deaths per 100,000 births by 2015.
In pursuit this goal, Marie Stopes International
(MSI), and the Population Council conducted a
study on the knowledge and practice of
misoprostol provision among pharmacy
workers, as part of the “Strengthening
Evidence for Programming on Unintended
Pregnancy” (STEP UP) research program.
This study is helping to guide strategies for
expanding provision and proper delivery in
pharmacies of misoprostol, a drug which is
highly effective and acceptable for treating
PPH and post-abortion complications.
Misoprostol is included on the List of Essential
Medicines of the WHO and of Senegal.
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METHODOLOGY
A survey was conducted among 110
pharmacy owners, managers, or
employees in September 2013 to assess
the knowledge, attitudes and practice on:
1) Availability of misoprostol;
2) Knowledge of misoprostol;
3) Reported misoprostol provision
practices.
Fieldwork was conducted in September
2013.

RESULTS
Knowledge of Misoprostol
Respondents were generally under-informed of the many
uses of misoprostol.
 The majority (75%) knew the product can be used to
treat gastric ulcers but only 13% were aware it can be
used for PAC.
 Knowledge of the drug’s use in preventing and treating
PPH was also low (1% and 4% respectively).
 Other gynaecological uses, such as cervical ripening
(3%) and treatment of intrauterine foetal deaths (1%)
were not well known either.
This lack of knowledge suggests that the full range of
uses for misoprostol are not well-understood by pharmacy
workers in Senegal. Education is needed to take
advantage of the potential reduction in maternal mortality
and morbidity that the product can deliver.
Another gap in knowledge related to side effects of the
product.
 Only 14% cited dizziness and 13% bleeding as side
effects.
 Almost half of the respondents (47%) stated that they
were unaware of the existence of any side effects of
misoprostol.
Without this knowledge, pharmacy workers cannot
appropriately counsel clients, raising potential health risks.
Furthermore, few respondents were aware of the proper
dosages of misoprostol for specific conditions:
 38% of pharmacy workers reported knowing the
correct dosage for misoprostol as a treatment for
gastric ulcers. Of these, only 83% were able to
correctly identify the proper dosage of 800 mcg.
 14% of respondents reported that they knew the
proper dosage for PAC. Yet, only 4% of these
respondents correctly stated a dosage of between 400
and 600 mcg.
 No respondents reported knowing the correct dosage
for the prevention and treatment of PPH.
These results are concerning because without proper
dosing, both the efficacy and the safety of misoprostol
may be jeopardized.
Storage is also an important factor in drug efficacy.
Generally, respondents had partial understanding of
storage requirements. While 84% of them knew that
misoprostol should be kept away from heat, only 28%
were aware that it must also be kept away from humidity.

The full potential of misoprostol has not yet
been realised in Senegal. With increased
pharmacy worker education on the drug,
important progress could rapidly be made
in the reduction of maternal mortality
and morbidity.

The lack of knowledge about misoprostol may be explained
in part by the sources of information about the drug. Almost
half (45%) of respondents reported that they self-trained on
the uses of the product through literature, brochures, etc.
Others received information through medical delegates (22%)
and colleagues (20%). Only 10% of respondents received
information during university training. Other information
sources included doctors, clients, television, and the internet.
Recognizing their lack of knowledge about the medication,
85% of respondents desired further support and training on
misoprostol. Many stated that they needed information about
all aspects of the product (58%). More specific requests for
information where about uses (37%), side effects (30%),
complications (30%), and dosage (28%). Worryingly, even
though respondents were not confident in their knowledge,
they reported providing information to a range of providers,
including midwives (75%), gynaecologists (42%), nurses
(33%), and general practitioners (17%). This suggests the
potential for diffusion of misinformation among medical
professionals, and ultimately increased risk for patients.
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Provision of Misoprostol
Twenty-seven (27) respondents reported selling
misoprostol in their pharmacy (34% of the sample).
However, 48% of those who were not selling the product
did express the desire to do so.

Figure 2: Reasons for not selling
misoprostol
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The majority of sales were for the treatment of gastric
ulcers, reported by 63% of carriers of misoprostol. An
average of 58 tablets was sold per month per pharmacy
for all indications. Pharmacy workers who reported that
they do not sell misoprostol were asked to explain why.
The main reasons are presented in Figure 2 (right).
The three brands of misoprostol available on the
Senegalese market at the time of the study were:
Arthrotec, Cytotec and Misoclear.
 Arthrotec was the most widely sold (in 56% of
pharmacies that sold misoprostol). Arthrotec is a
combination medicine with diclofenac that is registered
for the treatment of gastric ulcers.
 Cytotec, also used to treat gastric ulcers, was available
at 41% of pharmacies.
 And, finally, Misoclear, which has been registered for
additional gynaecological uses such as PAC and PPH,
was available at 19% of pharmacies.
Respondents reported that they decided on the types of
misoprostol sold in their pharmacy based on what they
know about the product’s efficacy and availability in the
supply chain. It will only be possible for misoprostol to
contribute to a reduction in the maternal mortality ratio if
there is increased knowledge of misoprostol’s indications
and increased availability of the product.
A fifth (22%) of pharmacy workers reported that they had
experienced clients asking for the medication without a
prescription, but only one reported selling it in this
situation.
The majority (78%) of respondents believed that
customers can afford the price of misoprostol, which is 9
USD per box for Arthrotec, 27 USD per box for Cytotec
and 4 USD per box for Misoclear.
The majority of sales were for the treatment of gastric
ulcers, reported by 63% of carriers of misoprostol. An
average of 58 tablets was sold per month per pharmacy
for all indications.
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DISCUSSION
The pharmacy worker’s role is vital for the health of the
general population. As a contact point for the public, it
is important that pharmacy workers have a good
understanding and a proper supply of misoprostol.
A number of conclusions and recommendations can be
drawn from this study. They can be grouped under the
following categories:
Increased communication:
Even though the majority of pharmacy workers were
aware of the use of misoprostol for gastric and
duodenal ulcers, few knew of its gynecological
applications. This suggests that the national approval
of Misoclear for gynecological uses in 2011 has yet to
be widely disseminated. To facilitate quicker diffusion
of new policies and regulations, it is recommended that
communication within the supply chain be
strengthened, starting at the Pharmacy and Medicine
Division of the Ministry of Health (MoH). This includes
the dissemination of the List of Essential Medicines by
the MoH, which will clarify the uses of misoprostol and
has the potential to help de-stigmatize it.
Increased education:
The study revealed a general lack of knowledge
regarding the proper dosage of misoprostol for all
treatments. Additionally, almost half of respondents
were unable to name any side effects at all. This is a
potential risk for consumers. Many respondents
expressed the need for further training on misoprostol
and its usages, especially for gynecological purposes.
It is recommended that training sessions for
pharmaceutical personnel be implemented.



Increased availability of misoprostol in pharmacies:
Despite willingness to provide misoprostol, a low
percentage of pharmacy workers reported stocking
misoprostol at the time of the study due to low demand
and stock outs. Low demand for misoprostol may
reflect low numbers of prescriptions by health
providers. Further studies among health providers are
needed to explore how to increase prescription and use
of misoprostol in the fight against maternal morbidity
and mortality.
Pharmacists and distributors have a key role to play in
ensuring there is no stock out of the product, by
responding effectively and continuously to demand.
Recently, steps taken in Senegal to strengthen the
supply chain have been successful in preventing stock
outs of contraceptives. Similar efforts are required to
strengthen the supply chain for other important
medications for reducing maternal mortality such as
misoprostol.

CONCLUSION
The Senegalese government has made significant
efforts in the fight against maternal morbidity and
mortality. However, at the time of the study, misoprostol
was not yet widely available in the public health
system.
Amplified communication about the product can
contribute to an increase in demand from providers in
all sectors. However, as demand for the product
increases, the supply chain must be strengthened to
respond effectively and avoid shortages.
The Ministry of Health has committed to working with
the Order and Syndicate of Pharmacies to ensure the
availability of essential medicines, including
misoprostol, and to train pharmacy workers to allow
them to sell misoprostol safely for gynaecological
purposes. Misoprostol has a significant role to play in
reducing maternal mortality, but it must be made more
available at the points where people most commonly
access the health system, including pharmacies.

KEY RECOMMENDATIONS
 Strengthen communication between the
Pharmacy and Medicine Division of the
Ministry of Health and drug suppliers to
facilitate quicker diffusion of new laws
and regulations.
 Disseminate widely the List of Essential
Medicines to health providers and
pharmacy workers to increase
knowledge, and decrease
misconceptions, about priority drugs
and their indications in the Senegalese
context.
 Hold training sessions for
pharmaceutical personnel to increase
knowledge of medications on the List of
Essential Medicines, in particular
misoprostol.
 Increase the availability of misoprostol
among drug distributors and in
pharmacies to respond effectively to
demand and avoid shortages.
 Conduct further studies about
knowledge and uses of misoprostol
among health providers, as they are
able to prescribe misoprostol, to
explore ways to increase prescription
and uses.
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